BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2017 4:40:00 PM | Browse: 1347 | Download: 2363
 |
Received |
|
2016-06-21 09:58 |
|
Peer-Review Started |
|
2016-06-24 17:45 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-08-11 15:30 |
|
Revised |
|
2016-08-30 03:45 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-10-14 14:23 |
|
Second Decision by Editor-in-Chief |
|
2016-10-14 23:59 |
|
Final Decision by Editorial Office Director |
|
2016-10-27 17:29 |
|
Articles in Press |
|
2016-10-27 17:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-01-12 17:24 |
|
Publish the Manuscript Online |
|
2017-01-20 16:40 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Chi L Chang, Shet Masih, Anusha Thadi, Viren Patwa, Apoorva Joshi, Harry S Cooper, Vaseem A Palejwala, Margie L Clapper and Kunwar Shailubhai |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Cancer Institute |
CA 133689 |
| National Cancer Institute |
CA 006927 |
|
| Corresponding Author |
Kunwar Shailubhai, Doctor of Philosophy, Chief Scientific Officer, R and D Center, Synergy Pharmaceuticals Inc., 3805 Old Easton Road, Doylestown, PA 18902, United States. shailu@synergypharma.com
|
| Key Words |
Guanylate cyclase-C; Uroguanylin; Plecanatide; Inflammation; Colorectal cancer |
| Core Tip |
Plecanatide, an analog of human uroguanylin, binds and activates guanylate cyclase-C signaling to produce its anti-tumorigenic activity. This study provides the first evidence that oral treatment with plecanatide inhibits inflammation-driven colorectal carcinogenesis. The potential mechanism in Apc+/Min?FCCC mice appears to be agonist-mediated activation of guanylate cyclase-C signaling, resulting in inhibition of Wnt/b-catenin pathway and downregulation of pro-inflammatory cytokines and growth factors.
|
| Publish Date |
2017-01-20 16:40 |
| Citation |
Chang WCL, Masih S, Thadi S, Patwa V, Joshi A, Cooper HS, Palejwala VA, Clapper ML, Shailubhai K. Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice. World J Gastrointest Pharmacol Ther 2017; 8(1): 47-59 |
| URL |
http://www.wjgnet.com/2150-5349/full/v8/i1/47.htm |
| DOI |
http://dx.doi.org/10.4292/wjgpt.v8.i1.47 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
